Narrative review / 2007
FDA found no credible evidence for lycopene and cancer reduction, and only very limited evidence linking tomato intake to reduced risks of four cancers.
The U.S. FDA evaluated scientific evidence submitted in petitions for qualified health claims regarding tomato and lycopene consumption and cancer risk. The agency found no credible evidence to support an association between lycopene intake and reduced risk of prostate, lung, colorectal, gastric, breast, ovarian, endometrial, or pancreatic cancer. Additionally, no credible evidence supported an association between tomato consumption and reduced risk of lung, colorectal, breast, cervical, or endometrial cancer. The FDA identified only very limited evidence supporting an association between tomato consumption and reduced risks of prostate, ovarian, gastric, and pancreatic cancers.
Shows an association, not proof of cause and effect.
- Study type
- Evidence-based regulatory review
- Who was studied
- Human studies reviewed for FDA qualified health claim petitions
- What was measured
- Risk reduction for various forms of cancer
THE PAPER
The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer.
Kavanaugh CJ, Trumbo PR, Ellwood KC. J Natl Cancer Inst, 2007.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.